Rivastigmine for system suitability
European Pharmacopoeia (EP) Reference Standard
Manufacturer: Sigma Aldrich
CAS Number: 129101-54-8
Synonym(S): Rivastigmine tartrate, ENA-713, Ethylmethyl-carbamic acid 3-[(1S)-1-(dimethylamino)ethyl]phenyl ester, N-Ethyl-N-methyl-carbamic acid 3-[(1S)-1-(dimethylamino)ethyl]phenyl ester tartrate, S-Rivastigmine tartrate
Select a Size
| Pack Size | SKU | Availability | Price |
|---|---|---|---|
| 1.01 MG | Y0001485-1.01-MG | In Stock | ₹ 15,966.88 |
Y0001485 - 1.01 MG
In Stock
Quantity
1
Base Price: ₹ 15,966.88
GST (18%): ₹ 2,874.038
Total Price: ₹ 18,840.918
grade
pharmaceutical primary standard
API family
rivastigmine
manufacturer/tradename
EDQM
application(s)
pharmaceutical (small molecule)
format
neat
storage temp.
2-8°C
InChI
1S/C14H22N2O2.C4H6O6/c1-6-16(5)14(17)18-13-9-7-8-12(10-13)11(2)15(3)4;5-1(3(7)8)2(6)4(9)10/h7-11H,6H2,1-5H3;1-2,5-6H,(H,7,8)(H,9,10)/t11-;1-,2-/m00/s1
InChI key
GWHQHAUAXRMMOT-RWALOXMOSA-N
Other Options
| Image | Product Name | Manufacturer | Price Range | |
|---|---|---|---|---|
Sigma Aldrich Fine Chemicals Biosciences Rivastigmine hydrogen tartrate European Pharmacopoeia (EP) Reference Standard | 129101-54-8 | | -- | ₹ 16,681.27 | ||
Sigma Aldrich Fine Chemicals Biosciences Rivastigmine tartrate United States Pharmacopeia (USP) Reference Standard | 129101-54-8 | 200MG | -- | ₹ 1,27,074.20 | ||
eMolecules Ambeed / (S)-3-(1-(Dimethylamino)ethyl)phenyl ethyl(methyl)carbamate (2R3R)-23-dihydroxysuccinate / 10mg / 598442085 / A193069 / / 129101-54-8 / MFCD03700731 / 400.428 / C18H28N2O8 | -- | ₹ 2,057.68 | ||
Medchemexpress LLC HY-11017 50mg Medchemexpress, Rivastigmine (tartrate) CAS:129101-54-8 Purity:>98% | -- | ₹ 7,382.55 | ||
Rivastigmine hydrogen tartrate | -- | ₹ 14,072.50 | ||
Rivastigmine hydrogen tartrate | -- | ₹ 17,817.95 | ||
Carbamic acid, N-ethyl-N-methyl-, 3-[(1S)-1-(dimethylamino)ethyl]phenyl ester, (2R,3R)-2,3-dihydroxybutanedioate (1:1) | -- | ₹ 623.00 - ₹ 80,100.00 | ||
Rivastigmine tartrate | -- | ₹ 8,989.00 - ₹ 29,904.00 |
Description
- General description: This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
- Application: Rivastigmine for system suitability EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
- Biochem/physiol Actions: Rivastigmine is an orally available, brain penetrant, reversible cholinesterase inhibitor that enhances cognitive function in patients with Alzheimer′s and Parkinson′s diseases. Rivastigmine inhibits both butyrylcholinesterase and acetylcholinesterase.
- Packaging: The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
- Other Notes: Sales restrictions may apply.
SAFETY INFORMATION
Pictograms
Signal Word
Danger
Hazard Statements
Precautionary Statements
Hazard Classifications
Acute Tox. 2 Oral - Aquatic Chronic 2
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable